Imugene, Merck To Evaluate HER-Vaxx - KEYTRUDA Combination In Phase 2 Trial For Gastric Cancer

KENILWORTH (NJ) (dpa-AFX) - Imugene (IMU.AX) said that it has reached a new clinical trial collaboration and supply agreement with Merck & Co Inc. (MRK) to evaluate the safety and efficacy of Imugene's

Related Keywords

,Merck Co Inc ,Imugene ,Merck ,Valuate ,Vaxx ,Keytruda ,Combination ,Hase ,Trial ,Pastric ,Dancer ,